MB
TCRR

MPM BioImpact’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

MPM BioImpact’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,370,982
Closed -$5.06M – 39
2023
Q1 		$5.06M Hold
3,370,982
– – 1.31% 21
2022
Q4 		$3.37M Hold
3,370,982
– – 0.87% 25
2022
Q3 		$6.07M Hold
3,370,982
– – 1.44% 19
2022
Q2 		$9.78M Hold
3,370,982
– – 2.72% 9
2022
Q1 		$9.3M Hold
3,370,982
– – 2.5% 10
2021
Q4 		$15.7M Hold
3,370,982
– – 2.86% 9
2021
Q3 		$28.7M Hold
3,370,982
– – 4.45% 6
2021
Q2 		$55.3M Hold
3,370,982
– – 9.09% 3
2021
Q1 		$74.4M Hold
3,370,982
– – 9.35% 4
2020
Q4 		$104M Hold
3,370,982
– – 18.31% 1
2020
Q3 		$68.5M Hold
3,370,982
– – 16.5% 2
2020
Q2 		$51.8M Hold
3,370,982
– – 13.77% 3
2020
Q1 		$26.1M Hold
3,370,982
– – 15.94% 3
2019
Q4 		$48.1M Buy
+3,370,982
New +$52.1M 17.06% 3

MPM BioImpact's TCRR Position: Q2 2023 in Review

MPM BioImpact sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 3,370,982 shares — an estimated $5.06M sold.

MPM BioImpact first reported a position in TCRR in Q4 2019 and held it in 14 quarters. The position peaked at $104M in Q4 2020. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

  • MPM BioImpact reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • MPM BioImpact sold 3,370,982 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $5.06M.
  • MPM BioImpact first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2019 and held it in 14 quarters.
  • MPM BioImpact's TCR2 Therapeutics Inc. Common Stock position peaked at $104M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on MPM BioImpact's 13F filing for Q2 2023, filed 14 Aug 2023.